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Background
Allergen specific immunotherapy is an effective treatment
of allergic rhinitis. It is most commonly administered as
repeated subcutaneous injections or as a daily sublingual
tablet during 3-5 years. In order to shorten the treatment
duration previous studies have evaluated the use of intra-
lymphatic injections (ILIT) with promising results. This
study assesses safety and efficacy of ILIT with two aller-
gens given simultaneously.
Method
60 patients 2012-2014 with moderate to severe birch and
mild to moderate grass pollen allergy were recruited.
They were randomized 1:1 to three ultrasound guided
intralymphatic injections with placebo or ALK Alutard
Birch and Grass 1000 SQ/U in each groin with one-
month interval. The quality of life was assessed at peak
pollen season using the rhinitis related quality of life
(QoL) questionnaire Sinonasal Outcome test (SNOT-22).
Allergen specific IgE and IgG4 were monitored and flow
cytometry was used to characterize blood and lymph
node aspirate.
Results
36 patients have been analyzed so far (data from 2012-13).
14 patients received active treatment and 22 placebo.
Baseline characteristics including disease severity and QoL
were the same in both groups. All side effects reported
were mild; 8% of active patients had local swelling at injec-
tion site. In the placebo group the QoL scores worsened
during peak birch season (mean of difference between off
and during season: 19.70±4.60, n=20, p= 0.0004). In con-
trast, the scores remained unchanged in the active group
(6.27±4.72, n=11, p=0.21).S- Birch IgG4 levels increased
2 weeks after active ILIT (mean difference 0.26±0.11 mg/L,
p=0.04, n= 11). No such change was seen after placebo
(0 ±0.02 mg/L, p=0.97, n=17). S-Birch IgE levels increased
6-9 months after treatment in the active group (mean
difference 12,05±4.58 kU/ml, p=0.02, n=12) but not in the
placebo group (-0.05±5.1 kU/ml, p=0.99, n=21).Th1 cells
(indicated as CCR5+ CD4+ cells) increased in blood after
active ILIT (4.0±1.1%, p=0.04) but not after placebo
(-0.6±0.7, p=0.44). These cells also tended to increase in
the lymph node. Memory T-cells in blood also increased
following active treatment (p=0.05).
Conclusion
ILIT targeting birch and grass simultaneously appears to
be a safe procedure. The treatment improves the quality of
life during pollen season. This supports the idea of ILIT as
an effective alternative route for specific immunotherapy.
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